{
  "nctId": "NCT01862536",
  "briefTitle": "Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease",
  "officialTitle": "Tadalafil for Pulmonary Hypertension Associated With Chronic Lung Disease",
  "protocolDocument": {
    "nctId": "NCT01862536",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2019-03-25",
    "uploadDate": "2021-02-04T13:18",
    "size": 12328089,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT01862536/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "TRIPLE",
  "enrollmentInfo": {
    "enrollmentCount": 44,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2013-10-01",
    "completionDate": "2019-08-31",
    "primaryCompletionDate": "2019-08-31",
    "firstSubmitDate": "2013-05-15",
    "firstPostDate": "2013-05-24"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Male and female U.S. Veteran patients 40-85 years old, with Gold Stage II COPD by pulmonary function testing (FEV1/FVC \\<0.70; performed within 6 months of recruitment.\n* Eligible subjects must have PH documented on transthoracic echocardiogram within 6 months of baseline visit demonstrating an RV systolic pressure \\>40mmHg. To confirm the presence of PH, a right-heart catheterization will be performed, with subjects randomized to treatment only if catheterization shows a:\n\n  * mPAP \\>25 mm Hg\n  * PVR \\>2.5 Wood units\n  * pulmonary artery capillary wedge pressure 18 mm Hg or less at rest\n* PH belonging to the following subgroup of the updated Dana Point Clinical Classification:\n\n  * Group 3 (PH associated with lung disease and/or hypoxemia) specifically, Group 3.1 (chronic obstructive pulmonary disease \\[COPD\\]) as the major criteria. Patients may also have minor clinical features associated with 3.2 (Interstitial disease) (such as mild fibrosis on high resolution chest CT, but total lung capacity\\>80% predicted) and 3.3 (sleep disordered breathing) (AHI \\<15 or 20/hour).\n* 6-minute walk distance between 50-450 meters at screening visit.\n\nExclusion Criteria:\n\n* PH belonging to the following subgroups of the updated Dana Point Clinical Classification:\n\nGroup 1\n\n* Idiopathic\n* heritable\n* drug or toxin-induced\n* Associated Pulmonary Arterial Hypertension (APAH) with:\n\n  * connective tissue disease\n  * congenital heart disease\n  * or HIV\n\nGroup 2\n\n* left atrial hypertension\n\nGroup 4\n\n* chronic thromboembolic PH\n* or other forms of PH not associated with primary lung disease\n\nAlso\n\n* Patients with a history of systemic hypotension in the ambulatory setting (reproducible measurements of systolic blood pressure \\<89 mmHg) on chart review.\n* Patients with moderate or severe hepatic impairment (Child-Pugh B and C)\n* Patients with severe renal insufficiency (GFR \\<30 ml/min/1.73 m2)\n* Severe aortic stenosis (aortic valve area \\<1.0 cm2)\n* Patients with any acute or chronic impairment:\n\n  * (other than dyspnea), limiting the ability to comply with the study requirements, including the 6-minute walk test and right heart catheterization.\n* Patients with a recent stroke\n* Patients with untreated hypoxemia (SaO2 \\<92%) at rest\n* Patients with untreated moderate or severe obstructive sleep apnea (AHI\\>15)\n* Patients with any coagulopathy\n* Patients requiring nitrate therapy for any clinical indication\n* Patients with an active prescription for pulmonary vasodilator medication other than oxygen\n* Patients with a history of nonarteritic anterior ischemic optic neuropathy\n* Contraindication to tadalafil use including allergy to:\n\n  * any PDE-5 inhibitor\n  * anatomical deformations of the penis\n  * sickle cell anemia\n  * multiple myeloma\n  * leukemia\n  * bleeding disorders\n  * active peptic ulcer disease\n  * retinitis pigmentosa or other retinal disorders.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "40 Years",
    "maximumAge": "85 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in 6 Minute Walk Test",
        "description": "Change from baseline in distance walked in 6 minutes.",
        "timeFrame": "The change in distance walked when assessed at 3 months following trial initiation as compared to baseline, similarly at 6 months compared to baseline, at 9 months compared to baseline and at 12 months compared to baseline."
      }
    ],
    "secondary": [
      {
        "measure": "Maximum VO2",
        "description": "Measure of aerobic fitness on exercise assessed by cardiopulmonary exercise test.",
        "timeFrame": "12 months"
      },
      {
        "measure": "Pulmonary Vascular Resistance",
        "description": "Pulmonary vascular resistance assessed on right heart catheterization is a hemodynamic measurement of pulmonary vascular remodeling.",
        "timeFrame": "6 months"
      },
      {
        "measure": "Mean Pulmonary Artery Pressure",
        "description": "Mean pulmonary artery pressure assessed by right heart catheterization is a hemodynamic measurement of pulmonary hypertension severity.",
        "timeFrame": "6 months"
      },
      {
        "measure": "Tricuspid Annular Plane Excursion (TAPSE)",
        "description": "The tricuspid annular plane excursion is an echocardiographic measurement of right ventricular systolic dysfunction.",
        "timeFrame": "12 months"
      },
      {
        "measure": "St. George's Respiratory Questionnaire, Dyspnea and Health Related Quality of Life",
        "description": "Disease-specific instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. There are 50 items, 2 parts, (3 components). Each item is accorded a weight determined by the degree of distress accorded to each symptom or state described.\n\nScores range from 0-100, with higher scores indicating more limitations",
        "timeFrame": "12 months"
      },
      {
        "measure": "N-type Brain Natriuretic Peptide (BNP) Concentration",
        "description": "Plasma BNP concentration is a biochemical marker that correlates positively with pulmonary hypertension severity.",
        "timeFrame": "12 months"
      },
      {
        "measure": "Resting Hypoxemia",
        "description": "Changes to resting peripheral oxyhemoglobin saturation levels will be used to assess the safety of the study drug in patients with chronic lung diseases.",
        "timeFrame": "Early (4 hours and 3 days following treatment) and late (1, 3, 6, 9, 12 months following treatment)"
      },
      {
        "measure": "Exercise-induced Hypoxemia",
        "description": "Changes to peripheral oxyhemoglobin saturation levels on exercise will be used to assess the safety of the study drug in patients with chronic lung diseases.",
        "timeFrame": "12 months"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 8,
      "otherCount": 0,
      "totalCount": 9
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 79,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:26.348Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}